PPD and SNBL Announce Japanese Joint Venture

Published on: 

Applied Clinical Trials

PPD and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture.

Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. announced an agreement to form a joint venture, PPD-SNBL, that will provide clinical development services in Japan. Some of these services include Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

PPD-SNBL will combine SNBL’s clinical research division and PPD’s clinical development operations in Japan, and it will have offices in Tokyo, Osaka, and Kagoshima The transactions are subject to customary closing conditions and are expected to close in April 2015.



Read the full release here.